Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
COVID-19
adverse reactions
anticancer therapy
cancer
moderna vaccine
neutralizing antibodies
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
02
11
2022
received:
09
08
2022
accepted:
09
12
2022
medline:
31
3
2023
pubmed:
11
12
2022
entrez:
10
12
2022
Statut:
ppublish
Résumé
Patients with solid tumors have been a risk group since the beginning of the SARS-CoV-2 pandemic due to more significant complications, hospitalizations or deaths. The immunosuppressive state of cancer treatments or the tumor itself could influence the development of post-vaccination antibodies. This study prospectively analyzed 89 patients under chemotherapy and/or immunotherapy, who received two doses of the mRNA-1237 vaccine, and were compared with a group of 26 non-cancer individuals. Information on adverse events and neutralizing antibodies against the ancestral strain of SARS-CoV-2 (WH1) have been analyzed. Local reactions accounted for 65%, while systemic reactions accounted for 46% of oncologic individuals/cancer patients. Regarding the response to vaccination, 6.7% of cancer patients developed low neutralizing antibody levels. Lower levels of neutralizing antibodies between cancer and non-cancer groups were significant in individuals without previous SARS-CoV-2 infection, but not in previously infected individuals. We also observed that patients receiving chemotherapy or chemoimmunotherapy have significantly lower levels of neutralizing antibodies than non-cancer individuals. In conclusion, our study confirms the importance of prioritizing cancer patients receiving anticancer treatment in SARS-CoV-2 vaccination programs.
Identifiants
pubmed: 36495129
doi: 10.1002/1878-0261.13359
pmc: PMC9877816
doi:
Substances chimiques
Antibodies, Neutralizing
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-694Subventions
Organisme : Grifols
Organisme : Generalitat de Catalunya
ID : DSL016
Organisme : Spanish Health Institute Carlos III
ID : CM20/00027
Organisme : Spanish Health Institute Carlos III
ID : PI20/00093
Organisme : Spanish Health Institute Carlos III
ID : PI17/01518
Organisme : CERCA Programme/Generalitat de Catalunya
ID : 2017 SGR 252
Organisme : #joemcorono
Organisme : BonPreu/Esclat
Organisme : Correos
Organisme : National Agency for Research and Development of Chile
ID : 72180406
Organisme : Spanish Ministry of Science and Innovation and State Research Agency
Organisme : European Social Fund
Informations de copyright
© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
Ann Oncol. 2012 Feb;23(2):450-7
pubmed: 21576285
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Viruses. 2021 Mar 05;13(3):
pubmed: 33807957
Eur J Breast Health. 2021 Dec 30;18(1):85-90
pubmed: 35059596
Cancer Immunol Res. 2015 May;3(5):436-43
pubmed: 25941355
J Med Virol. 2021 Dec;93(12):6444-6446
pubmed: 34260066
Medicine (Baltimore). 2022 Jan 14;101(2):e28561
pubmed: 35029223
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Ann Oncol. 2011 Sep;22(9):2031-2035
pubmed: 21303799
Viruses. 2021 Jun 12;13(6):
pubmed: 34204754
Immunotherapy. 2016 Jun;8(7):821-37
pubmed: 27349981
Cancer Cell. 2022 Feb 14;40(2):117-119
pubmed: 34986328
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Sci Immunol. 2022 Feb 18;7(68):eabn8014
pubmed: 35076258
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Cancers (Basel). 2021 Aug 20;13(16):
pubmed: 34439346
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Curr Probl Cancer Case Rep. 2022 Jun;6:100153
pubmed: 35378738
Cell Rep Med. 2022 Jan 24;3(2):100523
pubmed: 35233547
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
Eur J Cancer. 2022 May;167:175-176
pubmed: 35370047
Lancet. 2021 Jul 17;398(10296):223-237
pubmed: 34274064
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
JAMA Oncol. 2022 Jan 1;8(1):114-122
pubmed: 34817562
Med. 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Br J Haematol. 2022 Feb;196(3):548-558
pubmed: 34649298
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33753569
Future Oncol. 2022 Feb;18(5):533-541
pubmed: 34825831
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Front Immunol. 2022 Apr 28;13:860215
pubmed: 35572570
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
J Clin Oncol. 2019 Oct 20;37(30):2795-2804
pubmed: 31465264
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Eur J Cancer. 2021 Nov;157:441-449
pubmed: 34601285
Lancet. 2022 Mar 5;399(10328):905-907
pubmed: 35090602
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EBioMedicine. 2021 Aug;70:103539
pubmed: 34391087
ESMO Open. 2021 Dec;6(6):100283
pubmed: 34634634
N Engl J Med. 2022 Jun 9;386(23):2201-2212
pubmed: 35613036
JAMA Netw Open. 2022 May 2;5(5):e2210880
pubmed: 35532936